Surgical resection of lung adenocarcinoma after crizotinib treatment: Report of a case

Kaoru Kaseda; Ken Ichi Watanabe; Keisuke Asakura; Akio Kazama

doi:10.1186/s12957-015-0480-2

Surgical resection of lung adenocarcinoma after crizotinib treatment: Report of a case

Kaoru Kaseda, Ken Ichi Watanabe, Keisuke Asakura, Akio Kazama

Research output: Contribution to journal › Article › peer-review

6 Citations (Scopus)

Abstract

A 45-year-old female was diagnosed as having lung adenocarcinoma harboring an anaplastic lymphoma kinase (ALK) rearrangement, stage IV (T2bN3M1b). She was treated with crizotinib as second-line chemotherapy. The clinical stage after crizotinib treatment was ycT2aN0M0, stage IB. We performed a left lower lobectomy and lymph node dissection aimed at local control and pathological confirmation of the remaining tumor. The final pathological stage was ypT2aN2M0, stage IIIA with Ef 1b. To the best of our knowledge, this is the first case report of surgical resection in ALK rearrangement-positive lung adenocarcinoma after crizotinib treatment.

Original language	English
Article number	74
Journal	World Journal of Surgical Oncology
Volume	13
Issue number	1
DOIs	https://doi.org/10.1186/s12957-015-0480-2
Publication status	Published - 2015 Feb 22
Externally published	Yes

Keywords

Anaplastic lymphoma kinase
Crizotinib
Non-small cell lung cancer
Salvage surgery

ASJC Scopus subject areas

Surgery
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1186/s12957-015-0480-2

Cite this

@article{696d445a46f54d8e90feffb31680e27d,

title = "Surgical resection of lung adenocarcinoma after crizotinib treatment: Report of a case",

abstract = "A 45-year-old female was diagnosed as having lung adenocarcinoma harboring an anaplastic lymphoma kinase (ALK) rearrangement, stage IV (T2bN3M1b). She was treated with crizotinib as second-line chemotherapy. The clinical stage after crizotinib treatment was ycT2aN0M0, stage IB. We performed a left lower lobectomy and lymph node dissection aimed at local control and pathological confirmation of the remaining tumor. The final pathological stage was ypT2aN2M0, stage IIIA with Ef 1b. To the best of our knowledge, this is the first case report of surgical resection in ALK rearrangement-positive lung adenocarcinoma after crizotinib treatment.",

keywords = "Anaplastic lymphoma kinase, Crizotinib, Non-small cell lung cancer, Salvage surgery",

author = "Kaoru Kaseda and Watanabe, {Ken Ichi} and Keisuke Asakura and Akio Kazama",

note = "Publisher Copyright: {\textcopyright} 2015 Kaseda et al.",

year = "2015",

month = feb,

day = "22",

doi = "10.1186/s12957-015-0480-2",

language = "English",

volume = "13",

journal = "World Journal of Surgical Oncology",

issn = "1477-7819",

publisher = "BioMed Central",

number = "1",

}

TY - JOUR

T1 - Surgical resection of lung adenocarcinoma after crizotinib treatment

T2 - Report of a case

AU - Kaseda, Kaoru

AU - Watanabe, Ken Ichi

AU - Asakura, Keisuke

AU - Kazama, Akio

PY - 2015/2/22

Y1 - 2015/2/22

N2 - A 45-year-old female was diagnosed as having lung adenocarcinoma harboring an anaplastic lymphoma kinase (ALK) rearrangement, stage IV (T2bN3M1b). She was treated with crizotinib as second-line chemotherapy. The clinical stage after crizotinib treatment was ycT2aN0M0, stage IB. We performed a left lower lobectomy and lymph node dissection aimed at local control and pathological confirmation of the remaining tumor. The final pathological stage was ypT2aN2M0, stage IIIA with Ef 1b. To the best of our knowledge, this is the first case report of surgical resection in ALK rearrangement-positive lung adenocarcinoma after crizotinib treatment.

AB - A 45-year-old female was diagnosed as having lung adenocarcinoma harboring an anaplastic lymphoma kinase (ALK) rearrangement, stage IV (T2bN3M1b). She was treated with crizotinib as second-line chemotherapy. The clinical stage after crizotinib treatment was ycT2aN0M0, stage IB. We performed a left lower lobectomy and lymph node dissection aimed at local control and pathological confirmation of the remaining tumor. The final pathological stage was ypT2aN2M0, stage IIIA with Ef 1b. To the best of our knowledge, this is the first case report of surgical resection in ALK rearrangement-positive lung adenocarcinoma after crizotinib treatment.

KW - Anaplastic lymphoma kinase

KW - Crizotinib

KW - Non-small cell lung cancer

KW - Salvage surgery

UR - http://www.scopus.com/inward/record.url?scp=84928691455&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928691455&partnerID=8YFLogxK

U2 - 10.1186/s12957-015-0480-2

DO - 10.1186/s12957-015-0480-2

M3 - Article

C2 - 25889062

AN - SCOPUS:84928691455

SN - 1477-7819

VL - 13

JO - World Journal of Surgical Oncology

JF - World Journal of Surgical Oncology

IS - 1

M1 - 74

ER -

Surgical resection of lung adenocarcinoma after crizotinib treatment: Report of a case

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this